Skip to content

Total at other companies

Amgen logo
AmgenAMGN
Arcus Biosciences logo
Arcus BiosciencesRCUS
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s total?
Arcutis Biotherapeutics, Inc. (ARQT) reported total of $189.48M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s total changed year-over-year?
Arcutis Biotherapeutics, Inc.'s total increased by 30.9% year-over-year, from $144.8M to $189.48M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total has grown at a -4.1% compound annual growth rate (CAGR), from $219.36M to $177.96M.